EVEROLIMUS vs TASIGNA

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated October 7, 2026·How we rate

Possible drug interaction. EVEROLIMUS and TASIGNA are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	EVEROLIMUS	TASIGNA
Rating	72/100	70/100
Pharmacy pays	~$219.28 /30	—
Type	RX	RX
Active ingredient	EVEROLIMUS	NILOTINIB HYDROCHLORIDE
Manufacturer	Biocon Pharma	Novartis
Dosage forms	Tablet	Capsule
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	Boxed warning	Boxed warning
Half-life	about 30 hours (mean terminal elimination half-life)	—
Treats	—	Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia

everolimus tasigna

Rating

72/100

70/100

Pharmacy pays

~$219.28 /30

—

Type

Active ingredient

EVEROLIMUS

NILOTINIB HYDROCHLORIDE

Manufacturer

Biocon Pharma

Novartis

Dosage forms

Tablet

Capsule

Drug class

Kinase Inhibitor

Boxed warning

Half-life

about 30 hours (mean terminal elimination half-life)

—

Treats

—

Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia

Frequently asked questions

Which is better-rated, Everolimus or Tasigna?

By our independent rating, Everolimus scores higher — 3.6 vs 3.5 out of 5 for Tasigna. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Everolimus and Tasigna?

Everolimus contains Everolimus, while Tasigna contains Nilotinib Hydrochloride — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.